UMCG-001

UMCG-001 is an academically developed, non-proprietary, third-generation autologous chimeric antigen receptor (CAR)-T cell therapy designed to target CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell prolymphocytic leukemia (T-PLL). The CAR construct utilizes the extracellular domain of K12 (SECTM1), the natural high-affinity ligand for CD7, as its binding domain, which is intended to provide a physiological interaction with reduced immunogenicity compared to traditional antibody-derived scFvs. The signaling architecture includes both 4-1BB and CD28 costimulatory domains alongside a CD3ζ signaling domain. A key feature of UMCG-001 is its unedited manufacturing process; rather than using gene editing (e.g., CRISPR/Cas9) to prevent fratricide (self-killing), the protocol employs a fratricide-driven enrichment strategy. This process, optimized with GMP-grade human platelet lysate (HPL), naturally selects for a CD7-low/negative CAR-T cell population that is resistant to self-cytotoxicity while maintaining potent anti-leukemic activity.

Other names

K12-based CD7 CAR-TK-12-based CD7 CAR-TK 12-based CD7 CAR-TCD7-targeted autologous CAR-T productCD-7-targeted autologous CAR-T productCD 7-targeted autologous CAR-T productSECTM1-based CD7 CAR-TSECTM-1-based CD7 CAR-TSECTM 1-based CD7 CAR-T